nodes	percent_of_prediction	percent_of_DWPC	metapath
Lubiprostone—CBR1—Azacitidine—Fludarabine—lymphatic system cancer	0.0307	0.514	CbGdCrCtD
Lubiprostone—CBR1—Azacitidine—Cytarabine—lymphatic system cancer	0.029	0.486	CbGdCrCtD
Lubiprostone—Blood potassium decreased—Mitoxantrone—lymphatic system cancer	0.029	0.0308	CcSEcCtD
Lubiprostone—Faecal incontinence—Carmustine—lymphatic system cancer	0.0235	0.025	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.0106	0.0112	CcSEcCtD
Lubiprostone—Urinary tract infection—Fludarabine—lymphatic system cancer	0.0101	0.0107	CcSEcCtD
Lubiprostone—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00991	0.0105	CcSEcCtD
Lubiprostone—Swelling—Carmustine—lymphatic system cancer	0.00976	0.0104	CcSEcCtD
Lubiprostone—Anorexia—Mechlorethamine—lymphatic system cancer	0.00972	0.0103	CcSEcCtD
Lubiprostone—Swelling—Mitoxantrone—lymphatic system cancer	0.00907	0.00965	CcSEcCtD
Lubiprostone—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00887	0.00943	CcSEcCtD
Lubiprostone—Malnutrition—Fludarabine—lymphatic system cancer	0.0081	0.00861	CcSEcCtD
Lubiprostone—Chest pain—Teniposide—lymphatic system cancer	0.00785	0.00834	CcSEcCtD
Lubiprostone—Oedema—Teniposide—lymphatic system cancer	0.00752	0.008	CcSEcCtD
Lubiprostone—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00752	0.00799	CcSEcCtD
Lubiprostone—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00751	0.00799	CcSEcCtD
Lubiprostone—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.0074	0.00787	CcSEcCtD
Lubiprostone—Tachycardia—Teniposide—lymphatic system cancer	0.00734	0.00781	CcSEcCtD
Lubiprostone—Malaise—Fludarabine—lymphatic system cancer	0.0073	0.00777	CcSEcCtD
Lubiprostone—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00727	0.00773	CcSEcCtD
Lubiprostone—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00721	0.00766	CcSEcCtD
Lubiprostone—Anorexia—Teniposide—lymphatic system cancer	0.00717	0.00762	CcSEcCtD
Lubiprostone—Cough—Fludarabine—lymphatic system cancer	0.00707	0.00752	CcSEcCtD
Lubiprostone—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00706	0.00751	CcSEcCtD
Lubiprostone—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00698	0.00742	CcSEcCtD
Lubiprostone—Myalgia—Fludarabine—lymphatic system cancer	0.0069	0.00733	CcSEcCtD
Lubiprostone—Discomfort—Fludarabine—lymphatic system cancer	0.00681	0.00725	CcSEcCtD
Lubiprostone—Dyspnoea—Teniposide—lymphatic system cancer	0.00671	0.00713	CcSEcCtD
Lubiprostone—Oedema—Fludarabine—lymphatic system cancer	0.00661	0.00703	CcSEcCtD
Lubiprostone—Decreased appetite—Teniposide—lymphatic system cancer	0.00654	0.00695	CcSEcCtD
Lubiprostone—Vomiting—Mechlorethamine—lymphatic system cancer	0.00649	0.0069	CcSEcCtD
Lubiprostone—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00648	0.00689	CcSEcCtD
Lubiprostone—Urinary tract infection—Carmustine—lymphatic system cancer	0.00645	0.00686	CcSEcCtD
Lubiprostone—Rash—Mechlorethamine—lymphatic system cancer	0.00643	0.00684	CcSEcCtD
Lubiprostone—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00643	0.00683	CcSEcCtD
Lubiprostone—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00639	0.0068	CcSEcCtD
Lubiprostone—Anorexia—Fludarabine—lymphatic system cancer	0.0063	0.0067	CcSEcCtD
Lubiprostone—Weight increased—Mitoxantrone—lymphatic system cancer	0.00629	0.00669	CcSEcCtD
Lubiprostone—Feeling abnormal—Teniposide—lymphatic system cancer	0.0062	0.00659	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00615	0.00654	CcSEcCtD
Lubiprostone—Nausea—Mechlorethamine—lymphatic system cancer	0.00606	0.00644	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00602	0.00641	CcSEcCtD
Lubiprostone—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00599	0.00638	CcSEcCtD
Lubiprostone—Abdominal pain—Teniposide—lymphatic system cancer	0.00595	0.00632	CcSEcCtD
Lubiprostone—Erythema—Bleomycin—lymphatic system cancer	0.00594	0.00632	CcSEcCtD
Lubiprostone—Dyspnoea—Fludarabine—lymphatic system cancer	0.00589	0.00627	CcSEcCtD
Lubiprostone—Oedema peripheral—Carmustine—lymphatic system cancer	0.00587	0.00624	CcSEcCtD
Lubiprostone—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00585	0.00622	CcSEcCtD
Lubiprostone—Dyspepsia—Fludarabine—lymphatic system cancer	0.00582	0.00619	CcSEcCtD
Lubiprostone—Decreased appetite—Fludarabine—lymphatic system cancer	0.00575	0.00611	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00571	0.00607	CcSEcCtD
Lubiprostone—Fatigue—Fludarabine—lymphatic system cancer	0.0057	0.00606	CcSEcCtD
Lubiprostone—Constipation—Fludarabine—lymphatic system cancer	0.00565	0.00601	CcSEcCtD
Lubiprostone—Pain—Fludarabine—lymphatic system cancer	0.00565	0.00601	CcSEcCtD
Lubiprostone—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00559	0.00594	CcSEcCtD
Lubiprostone—Hypersensitivity—Teniposide—lymphatic system cancer	0.00554	0.00589	CcSEcCtD
Lubiprostone—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00551	0.00586	CcSEcCtD
Lubiprostone—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00545	0.00579	CcSEcCtD
Lubiprostone—Asthenia—Teniposide—lymphatic system cancer	0.0054	0.00574	CcSEcCtD
Lubiprostone—Malaise—Bleomycin—lymphatic system cancer	0.00536	0.0057	CcSEcCtD
Lubiprostone—Mental disorder—Carmustine—lymphatic system cancer	0.00522	0.00555	CcSEcCtD
Lubiprostone—Erythema—Carmustine—lymphatic system cancer	0.00518	0.00551	CcSEcCtD
Lubiprostone—Malnutrition—Carmustine—lymphatic system cancer	0.00518	0.00551	CcSEcCtD
Lubiprostone—Cough—Bleomycin—lymphatic system cancer	0.00518	0.00551	CcSEcCtD
Lubiprostone—Diarrhoea—Teniposide—lymphatic system cancer	0.00515	0.00547	CcSEcCtD
Lubiprostone—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00512	0.00545	CcSEcCtD
Lubiprostone—Chest pain—Bleomycin—lymphatic system cancer	0.00506	0.00538	CcSEcCtD
Lubiprostone—Myalgia—Bleomycin—lymphatic system cancer	0.00506	0.00538	CcSEcCtD
Lubiprostone—Discomfort—Bleomycin—lymphatic system cancer	0.005	0.00531	CcSEcCtD
Lubiprostone—Mental disorder—Vincristine—lymphatic system cancer	0.00498	0.0053	CcSEcCtD
Lubiprostone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00487	0.00518	CcSEcCtD
Lubiprostone—Tremor—Carmustine—lymphatic system cancer	0.00486	0.00517	CcSEcCtD
Lubiprostone—Oedema—Bleomycin—lymphatic system cancer	0.00485	0.00515	CcSEcCtD
Lubiprostone—Erythema—Mitoxantrone—lymphatic system cancer	0.00482	0.00513	CcSEcCtD
Lubiprostone—Vomiting—Teniposide—lymphatic system cancer	0.00478	0.00509	CcSEcCtD
Lubiprostone—Asthenia—Fludarabine—lymphatic system cancer	0.00474	0.00504	CcSEcCtD
Lubiprostone—Rash—Teniposide—lymphatic system cancer	0.00474	0.00504	CcSEcCtD
Lubiprostone—Dermatitis—Teniposide—lymphatic system cancer	0.00474	0.00504	CcSEcCtD
Lubiprostone—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00472	0.00502	CcSEcCtD
Lubiprostone—Headache—Teniposide—lymphatic system cancer	0.00471	0.00501	CcSEcCtD
Lubiprostone—Anorexia—Bleomycin—lymphatic system cancer	0.00462	0.00491	CcSEcCtD
Lubiprostone—Diarrhoea—Fludarabine—lymphatic system cancer	0.00452	0.00481	CcSEcCtD
Lubiprostone—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00447	0.00476	CcSEcCtD
Lubiprostone—Nausea—Teniposide—lymphatic system cancer	0.00447	0.00475	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00442	0.0047	CcSEcCtD
Lubiprostone—Chest pain—Carmustine—lymphatic system cancer	0.00441	0.00469	CcSEcCtD
Lubiprostone—Myalgia—Carmustine—lymphatic system cancer	0.00441	0.00469	CcSEcCtD
Lubiprostone—Anxiety—Carmustine—lymphatic system cancer	0.0044	0.00468	CcSEcCtD
Lubiprostone—Malaise—Mitoxantrone—lymphatic system cancer	0.00435	0.00462	CcSEcCtD
Lubiprostone—Dyspnoea—Bleomycin—lymphatic system cancer	0.00432	0.0046	CcSEcCtD
Lubiprostone—Oedema—Carmustine—lymphatic system cancer	0.00423	0.0045	CcSEcCtD
Lubiprostone—Decreased appetite—Bleomycin—lymphatic system cancer	0.00421	0.00448	CcSEcCtD
Lubiprostone—Myalgia—Vincristine—lymphatic system cancer	0.00421	0.00448	CcSEcCtD
Lubiprostone—Cough—Mitoxantrone—lymphatic system cancer	0.00421	0.00447	CcSEcCtD
Lubiprostone—Vomiting—Fludarabine—lymphatic system cancer	0.0042	0.00447	CcSEcCtD
Lubiprostone—Rash—Fludarabine—lymphatic system cancer	0.00417	0.00443	CcSEcCtD
Lubiprostone—Dermatitis—Fludarabine—lymphatic system cancer	0.00416	0.00443	CcSEcCtD
Lubiprostone—Pain—Bleomycin—lymphatic system cancer	0.00414	0.00441	CcSEcCtD
Lubiprostone—Headache—Fludarabine—lymphatic system cancer	0.00414	0.0044	CcSEcCtD
Lubiprostone—Tachycardia—Carmustine—lymphatic system cancer	0.00413	0.00439	CcSEcCtD
Lubiprostone—Myalgia—Mitoxantrone—lymphatic system cancer	0.0041	0.00436	CcSEcCtD
Lubiprostone—Chest pain—Mitoxantrone—lymphatic system cancer	0.0041	0.00436	CcSEcCtD
Lubiprostone—Anxiety—Mitoxantrone—lymphatic system cancer	0.00409	0.00435	CcSEcCtD
Lubiprostone—Lethargy—Methotrexate—lymphatic system cancer	0.00407	0.00433	CcSEcCtD
Lubiprostone—Discomfort—Mitoxantrone—lymphatic system cancer	0.00405	0.00431	CcSEcCtD
Lubiprostone—Oedema—Vincristine—lymphatic system cancer	0.00404	0.0043	CcSEcCtD
Lubiprostone—Anorexia—Carmustine—lymphatic system cancer	0.00403	0.00429	CcSEcCtD
Lubiprostone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00399	0.00425	CcSEcCtD
Lubiprostone—Nervous system disorder—Vincristine—lymphatic system cancer	0.00396	0.00421	CcSEcCtD
Lubiprostone—Oedema—Mitoxantrone—lymphatic system cancer	0.00393	0.00418	CcSEcCtD
Lubiprostone—Nausea—Fludarabine—lymphatic system cancer	0.00393	0.00418	CcSEcCtD
Lubiprostone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.0039	0.00415	CcSEcCtD
Lubiprostone—Shock—Mitoxantrone—lymphatic system cancer	0.00387	0.00412	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00385	0.0041	CcSEcCtD
Lubiprostone—Anorexia—Vincristine—lymphatic system cancer	0.00385	0.00409	CcSEcCtD
Lubiprostone—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00384	0.00408	CcSEcCtD
Lubiprostone—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00382	0.00406	CcSEcCtD
Lubiprostone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.0038	0.00404	CcSEcCtD
Lubiprostone—Dyspnoea—Carmustine—lymphatic system cancer	0.00377	0.00401	CcSEcCtD
Lubiprostone—Anorexia—Mitoxantrone—lymphatic system cancer	0.00375	0.00399	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00368	0.00391	CcSEcCtD
Lubiprostone—Decreased appetite—Carmustine—lymphatic system cancer	0.00368	0.00391	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00365	0.00388	CcSEcCtD
Lubiprostone—Constipation—Carmustine—lymphatic system cancer	0.00362	0.00385	CcSEcCtD
Lubiprostone—Pain—Carmustine—lymphatic system cancer	0.00362	0.00385	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00358	0.00381	CcSEcCtD
Lubiprostone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00357	0.0038	CcSEcCtD
Lubiprostone—Decreased appetite—Vincristine—lymphatic system cancer	0.00351	0.00373	CcSEcCtD
Lubiprostone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00351	0.00373	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00349	0.00371	CcSEcCtD
Lubiprostone—Feeling abnormal—Carmustine—lymphatic system cancer	0.00349	0.00371	CcSEcCtD
Lubiprostone—Fatigue—Vincristine—lymphatic system cancer	0.00348	0.0037	CcSEcCtD
Lubiprostone—Asthenia—Bleomycin—lymphatic system cancer	0.00348	0.0037	CcSEcCtD
Lubiprostone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00346	0.00368	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00346	0.00368	CcSEcCtD
Lubiprostone—Pain—Vincristine—lymphatic system cancer	0.00345	0.00367	CcSEcCtD
Lubiprostone—Constipation—Vincristine—lymphatic system cancer	0.00345	0.00367	CcSEcCtD
Lubiprostone—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00342	0.00364	CcSEcCtD
Lubiprostone—Fatigue—Mitoxantrone—lymphatic system cancer	0.00339	0.00361	CcSEcCtD
Lubiprostone—Constipation—Mitoxantrone—lymphatic system cancer	0.00336	0.00358	CcSEcCtD
Lubiprostone—Pain—Mitoxantrone—lymphatic system cancer	0.00336	0.00358	CcSEcCtD
Lubiprostone—Abdominal pain—Carmustine—lymphatic system cancer	0.00334	0.00356	CcSEcCtD
Lubiprostone—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.0033	0.00351	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.0033	0.00351	CcSEcCtD
Lubiprostone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00324	0.00345	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00322	0.00342	CcSEcCtD
Lubiprostone—Abdominal pain—Vincristine—lymphatic system cancer	0.00319	0.0034	CcSEcCtD
Lubiprostone—Hypersensitivity—Carmustine—lymphatic system cancer	0.00312	0.00331	CcSEcCtD
Lubiprostone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00311	0.00331	CcSEcCtD
Lubiprostone—Vomiting—Bleomycin—lymphatic system cancer	0.00308	0.00328	CcSEcCtD
Lubiprostone—Rash—Bleomycin—lymphatic system cancer	0.00306	0.00325	CcSEcCtD
Lubiprostone—Dermatitis—Bleomycin—lymphatic system cancer	0.00305	0.00325	CcSEcCtD
Lubiprostone—Asthenia—Carmustine—lymphatic system cancer	0.00304	0.00323	CcSEcCtD
Lubiprostone—Hypersensitivity—Vincristine—lymphatic system cancer	0.00298	0.00316	CcSEcCtD
Lubiprostone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.0029	0.00308	CcSEcCtD
Lubiprostone—Asthenia—Vincristine—lymphatic system cancer	0.0029	0.00308	CcSEcCtD
Lubiprostone—Diarrhoea—Carmustine—lymphatic system cancer	0.00289	0.00308	CcSEcCtD
Lubiprostone—Nausea—Bleomycin—lymphatic system cancer	0.00288	0.00306	CcSEcCtD
Lubiprostone—Asthenia—Mitoxantrone—lymphatic system cancer	0.00282	0.003	CcSEcCtD
Lubiprostone—Dizziness—Carmustine—lymphatic system cancer	0.0028	0.00298	CcSEcCtD
Lubiprostone—Diarrhoea—Vincristine—lymphatic system cancer	0.00276	0.00294	CcSEcCtD
Lubiprostone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00269	0.00286	CcSEcCtD
Lubiprostone—Vomiting—Carmustine—lymphatic system cancer	0.00269	0.00286	CcSEcCtD
Lubiprostone—Dizziness—Vincristine—lymphatic system cancer	0.00267	0.00284	CcSEcCtD
Lubiprostone—Rash—Carmustine—lymphatic system cancer	0.00267	0.00284	CcSEcCtD
Lubiprostone—Dermatitis—Carmustine—lymphatic system cancer	0.00266	0.00283	CcSEcCtD
Lubiprostone—Headache—Carmustine—lymphatic system cancer	0.00265	0.00282	CcSEcCtD
Lubiprostone—Vomiting—Vincristine—lymphatic system cancer	0.00257	0.00273	CcSEcCtD
Lubiprostone—Rash—Vincristine—lymphatic system cancer	0.00255	0.00271	CcSEcCtD
Lubiprostone—Dermatitis—Vincristine—lymphatic system cancer	0.00254	0.00271	CcSEcCtD
Lubiprostone—Headache—Vincristine—lymphatic system cancer	0.00253	0.00269	CcSEcCtD
Lubiprostone—Nausea—Carmustine—lymphatic system cancer	0.00251	0.00267	CcSEcCtD
Lubiprostone—Vomiting—Mitoxantrone—lymphatic system cancer	0.0025	0.00266	CcSEcCtD
Lubiprostone—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00249	0.00264	CcSEcCtD
Lubiprostone—Rash—Mitoxantrone—lymphatic system cancer	0.00248	0.00264	CcSEcCtD
Lubiprostone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00248	0.00263	CcSEcCtD
Lubiprostone—Headache—Mitoxantrone—lymphatic system cancer	0.00246	0.00262	CcSEcCtD
Lubiprostone—Mental disorder—Methotrexate—lymphatic system cancer	0.00242	0.00257	CcSEcCtD
Lubiprostone—Erythema—Methotrexate—lymphatic system cancer	0.0024	0.00255	CcSEcCtD
Lubiprostone—Malnutrition—Methotrexate—lymphatic system cancer	0.0024	0.00255	CcSEcCtD
Lubiprostone—Nausea—Vincristine—lymphatic system cancer	0.0024	0.00255	CcSEcCtD
Lubiprostone—Dysgeusia—Methotrexate—lymphatic system cancer	0.00235	0.0025	CcSEcCtD
Lubiprostone—Nausea—Mitoxantrone—lymphatic system cancer	0.00234	0.00248	CcSEcCtD
Lubiprostone—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00223	0.00237	CcSEcCtD
Lubiprostone—Malaise—Methotrexate—lymphatic system cancer	0.00217	0.0023	CcSEcCtD
Lubiprostone—Cough—Methotrexate—lymphatic system cancer	0.0021	0.00223	CcSEcCtD
Lubiprostone—Chest pain—Methotrexate—lymphatic system cancer	0.00204	0.00217	CcSEcCtD
Lubiprostone—Myalgia—Methotrexate—lymphatic system cancer	0.00204	0.00217	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00203	0.00216	CcSEcCtD
Lubiprostone—Discomfort—Methotrexate—lymphatic system cancer	0.00202	0.00215	CcSEcCtD
Lubiprostone—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00192	0.00204	CcSEcCtD
Lubiprostone—Skin disorder—Methotrexate—lymphatic system cancer	0.0019	0.00202	CcSEcCtD
Lubiprostone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00189	0.00201	CcSEcCtD
Lubiprostone—Anorexia—Methotrexate—lymphatic system cancer	0.00187	0.00199	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00179	0.0019	CcSEcCtD
Lubiprostone—Dyspnoea—Methotrexate—lymphatic system cancer	0.00175	0.00186	CcSEcCtD
Lubiprostone—Dyspepsia—Methotrexate—lymphatic system cancer	0.00172	0.00183	CcSEcCtD
Lubiprostone—Decreased appetite—Methotrexate—lymphatic system cancer	0.0017	0.00181	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00169	0.0018	CcSEcCtD
Lubiprostone—Fatigue—Methotrexate—lymphatic system cancer	0.00169	0.0018	CcSEcCtD
Lubiprostone—Pain—Methotrexate—lymphatic system cancer	0.00168	0.00178	CcSEcCtD
Lubiprostone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00161	0.00172	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.0016	0.0017	CcSEcCtD
Lubiprostone—Abdominal pain—Methotrexate—lymphatic system cancer	0.00155	0.00165	CcSEcCtD
Lubiprostone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00144	0.00154	CcSEcCtD
Lubiprostone—Asthenia—Methotrexate—lymphatic system cancer	0.00141	0.0015	CcSEcCtD
Lubiprostone—Diarrhoea—Methotrexate—lymphatic system cancer	0.00134	0.00143	CcSEcCtD
Lubiprostone—Dizziness—Methotrexate—lymphatic system cancer	0.0013	0.00138	CcSEcCtD
Lubiprostone—Vomiting—Methotrexate—lymphatic system cancer	0.00125	0.00133	CcSEcCtD
Lubiprostone—Rash—Methotrexate—lymphatic system cancer	0.00124	0.00131	CcSEcCtD
Lubiprostone—Dermatitis—Methotrexate—lymphatic system cancer	0.00123	0.00131	CcSEcCtD
Lubiprostone—Headache—Methotrexate—lymphatic system cancer	0.00123	0.00131	CcSEcCtD
Lubiprostone—Nausea—Methotrexate—lymphatic system cancer	0.00116	0.00124	CcSEcCtD
